Portal de Periódicos da CAPES

A promising, novel index in the diagnosis and follow‐up of patent ductus arteriosus: Red cell distribution width‐to‐platelet ratio

2018; Wiley; Volume: 32; Issue: 9 Linguagem: Inglês

10.1002/jcla.22616

1098-2825

Buse Özer Bekmez, Cüneyt Tayman, Mehmet Büyüktiryaki, Aslıhan Köse Çetinkaya, Ufuk Çakır, Turan Derme,

Kawasaki Disease and Coronary Complications

Background The role of red cell distribution width‐to‐platelet ratio ( RPR ) has not previously been mentioned in reports on patent ductus arteriosus ( PDA ). Our objective was to evaluate whether RPR would have a role in the diagnosis and/or prediction of pharmacological closure of PDA . Methods Preterm infants’ gestational age ≤30 weeks and ≤1500 g who were given first ibuprofen treatment in the first week of life for hemodynamically significant PDA (hs PDA ) were included in the study. The patients were matched for gestational age, birthweight, and sex. Patients were subdivided into two groups based on the response to medical treatment (open and closed PDA ). Hemogram parameters were recorded before and after medical therapy. Groups were compared with regard to demographic and clinical characteristics and for three sequential hematological parameters. RPR was calculated. Patients with sepsis, anemia, perinatal asphyxia, and congenital/chromosomal anomaly were not included in the study. Results A total of 112 infants had medically treated hs PDA . Of those, ductus closed in 70 neonates (closed PDA ). A total of 96 infants constituted the control group. Mean gestational age and birthweight of the patients were 28.9 ± 2.4 weeks and 1207 ± 372 g. While RPR was significantly increased, PCT was lower in both hs PDA and open PDA groups ( P < 0.05 and P < 0.05, respectively). In multivariate analysis, high RPR ( OR 3.3, 95% CI 1.438‐5.872, P < 0.05) and RDS ( OR 2.9, 95% CI 1.903‐4.811, P < 0.01) were detected as independent risk factors for hs PDA . Conclusion Red cell distribution width‐to‐platelet ratio and PCT may be promising supportive tools for the diagnosis and prediction of pharmacotherapy success.